2. Membrane Transporter/Ion Channel Neuronal Signaling
  3. GABA Receptor Sodium Channel iGluR
  4. BTS 72664

BTS 72664 is a broad-spectrum, non-sedating, orally effective anticonvulsant. Its anticonvulsant effect mainly arises from enhancing GABAA receptor (GABAA receptor)-mediated chloride channel currents, while it exerts weak blocking effects on Na+ channels (Ki = 350 μM) and NMDA receptors (NMDA receptor) (IC50 = 43 μM). BTS 72664 prevents the elevation of extracellular glutamate, glycine and serine concentrations in neurons, reduces cerebral infarct size, promotes functional recovery, prevents multiple types of epileptic seizures, and has low sedative potential. BTS 72664 can be used for the research of epilepsy, stroke and migraine.

For research use only. We do not sell to patients.

BTS 72664

BTS 72664 Chemical Structure

CAS No. : 165383-52-8

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

BTS 72664 Related Antibodies

Top Publications Citing Use of Products

View All Sodium Channel Isoform Specific Products:

View All Isoforms
Nav1.1 Nav1.2 Nav1.3 Nav1.4 Nav1.5 Nav1.6 Nav1.7 Nav1.8 Nav1.9

View All iGluR Isoform Specific Products:

View All Isoforms
AMPA Receptor NMDA Receptor Kainate Receptor

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

BTS 72664 is a broad-spectrum, non-sedating, orally effective anticonvulsant. Its anticonvulsant effect mainly arises from enhancing GABAA receptor (GABAA receptor)-mediated chloride channel currents, while it exerts weak blocking effects on Na+ channels (Ki = 350 μM) and NMDA receptors (NMDA receptor) (IC50 = 43 μM). BTS 72664 prevents the elevation of extracellular glutamate, glycine and serine concentrations in neurons, reduces cerebral infarct size, promotes functional recovery, prevents multiple types of epileptic seizures, and has low sedative potential. BTS 72664 can be used for the research of epilepsy, stroke and migraine[1].

In Vitro

BTS 72664 (350 μM) weakly binds to voltage-gated Na+ channels in rat brain synaptosomal membranes with a Ki of 350 μM[1].
BTS 72664 (300 μM; 0-6 seconds) significantly reduces 86Rb+ efflux by 50% from depolarized, Ca2+-exposed rat brain synaptosomes[1].
BTS 72664 inhibits Veratridine (HY-N6691)-induced glutamate efflux from rat brain synaptosomes without altering basal efflux[1].
BTS 72664 (3-100 μM) weakly reduces NMDA-induced depolarization by ~20% in rat brain cortical wedges, with no significant activity at non-NMDA glutamate receptors[1].
BTS 72664 (0.3-300 μM) attenuates spontaneous epileptiform discharges in rat brain cortical wedges, with greater potency against Bicuculline (HY-N0219)-induced SEDs (IC50 94 μM for frequency) than Mg2+-removal-induced SEDs (IC50 189 μM for frequency)[1].
BTS 72664 (100 μM; 20-45 min) hyperpolarizes the resting membrane potential of rat hippocampal slice CA1 pyramidal neurons by a mean of 9.5 mV[1].
BTS 72664 (10-100 μM) attenuates NMDA-evoked currents in cultured Swiss mouse cortical neurons with an IC50 of 43 μM[1].
BTS 72664 (10-100 μM) potentiates GABA-evoked currents in cultured Swiss mouse cortical neurons via a benzodiazepine-independent, Picrotoxin (HY-101391)-sensitive GABAA channel mechanism, producing a 511% potentiation at 100 μM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BTS 72664 Related Antibodies
In Vivo

BTS 72664 (1.9-9.4 mg/kg; p.o.; single dose; daily; 5 days) potently protects against Bicuculline-induced seizures in mice with an ED50 of 1.9 mg/kg p.o. at peak effect, and no rapid tolerance develops with 5 days of daily dosing[1].
BTS 72664 (47.5-77.2 mg/kg; p.o.; single dose) protects against maximal electroshock-induced seizures in mice with an ED50 of 47.5 mg/kg p.o. at peak effect, has a duration of action of 4-6 hours, and is more potent at increasing seizure threshold than blocking seizure generalization[1].
BTS 72664 (14 mg/kg; p.o.; single dose) protects against pentylenetetrazol-induced seizures in mice with an ED50 of 14 mg/kg p.o., and is highly potent at increasing seizure initiation thresholds[1].
BTS 72664 (60 mg/kg; p.o.; single dose) protects against Picrotoxin-induced seizures in mice with an ED50 of 60 mg/kg p.o[1].
BTS 72664 (25 mg/kg; p.o.; single dose) protects against 4-aminopyridine (HY-B0604)-induced seizures in mice with an ED50 of 25 mg/kg p.o[1].
BTS 72664 (18 mg/kg; p.o.; single dose) protects against NMDA (HY-17551)-induced seizures in mice with an ED50 of 18 mg/kg p.o[1].
BTS 72664 (9 mg/kg; p.o.; single dose) protects against audiogenic seizures in DBA/2 mice with an ED50 of 9 mg/kg p.o[1].
BTS 72664 (29 mg/kg; p.o.; single dose) protects against seizures in GEPR-9 rats with an ED50 of 29 mg/kg p.o[1].
BTS 72664 (4.6 mg/kg; p.o.; single dose) protects against Bicuculline-induced seizures in rats with an ED50 of 4.6 mg/kg p.o., showing minimal species difference in potency compared to mice[1].
BTS 72664 (90 mg/kg; p.o.; single dose) protects against maximal electroshock-induced seizures in rats with an ED50 of 90 mg/kg p.o., showing minimal species difference in potency compared to mice[1].
BTS 72664 (100-150 mg/kg; p.o.; single dose) dose-dependently improves seizure parameters in amygdala-kindled rats, with a 150 mg/kg p.o. dose producing a 177% increase in seizure threshold and 65% reduction in seizure duration[1].
BTS 72664 (50 mg/kg; p.o.; every 12 hours; 4 total doses), starting 15 min post-occlusion, reduces ischemic lesion volume by 31% and accelerates functional recovery in Rattus norvegicus with permanent middle cerebral artery occlusion[1].
BTS 72664 (20-35 mg/kg; i.p.; single initial dose; every 12 hours; 3 subsequent doses), starting 60 min post-occlusion, reduces ischemic lesion volume by 40% in rats with permanent middle cerebral artery occlusion, with no hypothermic contribution to neuroprotection[1].
BTS 72664 (50 mg/kg; p.o.; single dose), administered 15 min post-cortical insult, rapidly and persistently abolishes cortical spreading depression-associated increases in extracellular glutamate, glycine, and serine in rats[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Swiss CD1 mice[1]
Dosage: 1.9 mg/kg (30 min post-dose); 9.4 mg/kg (60 min post-dose); 2.8 mg/kg (chronic)
Administration: p.o.; single dose; p.o.; daily; 5 days
Result: Had an ED50 of 1.9 mg/kg p.o.
for protection against bicuculline-induced seizures at 30 min post-dose.
Had an ED50 of 9.4 mg/kg p.o.
for protection against bicuculline-induced seizures at 60 min post-dose.
Showed no significant attenuation of anticonvulsant efficacy after 5 consecutive days of 2.8 mg/kg p.o.
daily dosing compared to a single dose.
Animal Model: Swiss CD1 mice[1]
Dosage: 47.5 mg/kg (30 min post-dose); 77 mg/kg (60 min post-dose); 77.2 mg/kg (peak protection)
Administration: p.o.; single dose
Result: Had an ED50 of 47.5 mg/kg p.o.
for protection against maximal electroshock-induced seizures at 30 min post-dose.
Had an ED50 of 77 mg/kg p.o.
for protection against maximal electroshock-induced seizures at 60 min post-dose.
Provided peak protection against maximal electroshock-induced seizures at 30 min post-dose with a duration of action of 4-6 hours at 77.2 mg/kg p.o.
Had a TID20 of 5.7 mg/kg p.o.
for increasing seizure current threshold by 20%.
Animal Model: Swiss CD1 mice[1]
Dosage: 14 mg/kg
Administration: p.o.; single dose
Result: Had an ED50 of 14 mg/kg p.o.
for protection against subcutaneous pentylenetetrazol-induced seizures.
Had a TID20 of 5.6 mg/kg p.o.
for increasing pentylenetetrazol-induced initial myoclonic twitch threshold by 20%.
Had a TID20 of 1.1 mg/kg p.o.
for increasing pentylenetetrazol-induced generalized clonic seizure threshold by 20%.
Animal Model: Swiss CD1 mice[1]
Dosage: 60 mg/kg
Administration: p.o.; single dose
Result: Had an ED50 of 60 mg/kg p.o.
for protection against subcutaneous picrotoxin-induced seizures.
Animal Model: Swiss CD1 mice[1]
Dosage: 25 mg/kg
Administration: p.o.; single dose
Result: Had an ED50 of 25 mg/kg p.o.
for protection against intracerebroventricular 4-aminopyridine-induced seizures.
Animal Model: Swiss CD1 mice[1]
Dosage: 18 mg/kg
Administration: p.o.; single dose
Result: Had an ED50 of 18 mg/kg p.o.
for protection against intracerebroventricular NMDA-induced seizures.
Animal Model: DBA/2 mice[1]
Dosage: 9 mg/kg
Administration: p.o.; single dose
Result: Had an ED50 of 9 mg/kg p.o.
for protection against audiogenic seizures in DBA/2 mice.
Animal Model: GEPR-9 rats[1]
Dosage: 29 mg/kg
Administration: p.o.; single dose
Result: Had an ED50 of 29 mg/kg p.o.
for protection against seizures in GEPR-9 rats.
Animal Model: Rats[1]
Dosage: 4.6 mg/kg
Administration: p.o.; single dose
Result: Had an ED50 of 4.6 mg/kg p.o.
for protection against bicuculline-induced seizures in rats.
Animal Model: Rats[1]
Dosage: 90 mg/kg
Administration: p.o.; single dose
Result: Had an ED50 of 90 mg/kg p.o.
for protection against maximal electroshock-induced seizures in rats.
Animal Model: Rats[1]
Dosage: 100 mg/kg; 150 mg/kg
Administration: p.o.; single dose
Result: Increased mean kindled seizure threshold by 68% at 100 mg/kg p.o.
Increased mean kindled seizure threshold by 177% at 150 mg/kg p.o.
Reduced mean seizure severity by 59% at 150 mg/kg p.o.
Reduced mean seizure duration by 65% (from 69 to 24 sec) at 150 mg/kg p.o.
Reduced mean afterdischarge duration by 68% (from 105 to 34 sec) at 150 mg/kg p.o.
Caused mild ataxia at 150 mg/kg p.o.
but no significant motor impairment in the rotarod test.
Animal Model: Rats[1]
Dosage: 50 mg/kg
Administration: p.o.; every 12 hours; 4 total doses
Result: Reduced cerebral lesion volume by 31% (treated: 56.9 mm3; vehicle: 82.6 mm3) at 2 days post-insult.
Showed a significant reduction in contralateral forelimb faults on day 8 post-insult, and when data from days 3, 6, and 8 were combined, compared to vehicle-treated controls.
Animal Model: Rats[1]
Dosage: 20 mg/kg (subsequent doses); 35 mg/kg (initial dose)
Administration: i.p.; single initial dose; i.p.; every 12 hours; 3 subsequent doses
Result: Reduced cerebral lesion volume by 40% (treated: 43.6 mm3; vehicle: 72.0 mm3) at 6 days post-insult.
Did not decrease core body temperature when monitored for 18 hours after the initial 35 mg/kg i.p.
dose.
Animal Model: Rats[1]
Dosage: 50 mg/kg
Administration: p.o.; single dose
Result: Abolished the transient, insult-induced increases in extracellular glutamate, glycine, and serine levels in the parietal cortex.
Did not alter extracellular GABA levels, but reduced extracellular glutamate levels compared to basal values in anesthetic-only controls.
Exhibited a rapid onset (30 min post-administration) and effect lasting for at least 2.25 hours from peak brain levels.
Molecular Weight

274.71

Formula

C13H11ClN4O
CAS No.
SMILES

ClC(C=C1)=CC=C1O[C@@H](C2=CC=NC3=NC=NN23)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

BTS 72664 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BTS 72664165383-52-8BTS72664BTS-72664GABA ReceptorSodium ChanneliGluRGamma-aminobutyric acid Receptorγ-Aminobutyric acid ReceptorNa channelsNa+ channelsIonotropic glutamate receptorsNMDA channelrat brain synaptosomal membranessodium channelmigraineSwiss mouse cortical neuronschloride channelepilepsystrokerat hippocampal slice CA1 pyramidal neuronshuman lymphocyteInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
BTS 72664
Cat. No.:
HY-182548
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.